← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1999Last known activity
Feb 7, 2025
Acquired by Otsuka on Oct 11, 2013
Timeline
1990s
- Jan 1, 1999
Astex Pharmaceuticals, Inc.— Founded
2010s
- Oct 11, 2013
Otsuka— Acquired By
Drugs by trial phase (61 distinct, 95 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (35 own, 0 via acquisition)
Phase 1 (14 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Blast Crisis
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Central Nervous System Neoplasms
- Colorectal Neoplasms
- Esophageal Neoplasms
- Gastrointestinal Stromal Tumors
- Graft vs Host Disease
- Hodgkin Disease
- Intestinal Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lung Neoplasms
- Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Multiple Myeloma
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm, Residual
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Sarcoma
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Syndrome
- Triple Negative Breast Neoplasms
- Undifferentiated Connective Tissue Diseases
Recent trials (50)
- NCT06802146CollaboratorEarly Phase 1Feb 7, 2025
- NCT06297629CollaboratorPhase 2Jul 1, 2024
- NCT06191978CollaboratorPhase 1Mar 7, 2024
- NCT05835011Lead sponsorPhase 2Jul 14, 2023
- NCT05360160CollaboratorPhase 1/Phase 2Oct 14, 2022
- NCT05456269CollaboratorPhase 1Jul 31, 2022
- NCT05403450Lead sponsorPhase 1/Phase 2Jun 23, 2022
- NCT05245682CollaboratorEarly Phase 1Feb 17, 2022
- NCT05007873CollaboratorPhase 2Dec 30, 2021
- NCT05082259CollaboratorPhase 1Dec 1, 2021
- NCT04953897Lead sponsorPhase 1Sep 30, 2021
- NCT04953910Lead sponsorPhase 1Sep 30, 2021
- NCT04953923Lead sponsorPhase 1Jul 1, 2021
- NCT04857645CollaboratorPhase 2Jun 22, 2021
- NCT04872543CollaboratorPhase 2Apr 29, 2021
Details
- Founded
- Cambridge, GB Jan 1, 1999
- Last known activity
- Feb 7, 2025
Notes
formed through the merger of Astex Therapeutics Limited (UK) and SuperGen, Inc. (US) in 2011 --- Pre-folding founded info: 2011-01-01 Dublin CA US https://astx.com/discover-astex/our-history/ ---